[1]	潘慧, 杜红伟. 重组人生长激素临床应用的安全性思考[J]. 中国当代儿科杂志, 2024, 26(5): 444-449. PMCID: PMC11135066. DOI: 10.7499/j.issn.1008-8830.2310001 . https://www.ncbi.nlm.nih.gov/pubmed/38802902 本文引用 [3]

[2]	Ferruzzi A, Vrech M, Pietrobelli A, et al. The influence of growth hormone on pediatric body composition: a systematic review[J]. Front Endocrinol (Lausanne), 2023, 14: 1093691. PMCID: PMC9947344. DOI: 10.3389/fendo.2023.1093691 . https://www.ncbi.nlm.nih.gov/pubmed/36843617 本文引用 [2]

[3]

Yuan Y, Zhou B, Liu S, et al. Meta-analysis of metabolic changes in children with idiopathic growth hormone deficiency after recombinant human growth hormone replacement therapy[J]. Endocrine, 2021, 71(1): 35-46. DOI: 10.1007/s12020-020-02435-w . https://www.ncbi.nlm.nih.gov/pubmed/32740695 本文引用 [2]

[4]	Frixou M, Vlek D, Lucas-Herald AK, et al. The use of growth hormone therapy in adults with Prader-Willi syndrome: a systematic review[J]. Clin Endocrinol (Oxf), 2021, 94(4): 645-655. DOI: 10.1111/cen.14372 . https://www.ncbi.nlm.nih.gov/pubmed/33296095 本文引用 [3]

[5]

Shen YY, Ma JN, Ren ZY, et al. Effects of 18 months of growth hormone replacement therapy on bone mineral density in patients with adult growth hormone deficiency: a retrospective study[J]. Int J Endocrinol, 2023, 2023: 4988473. PMCID: PMC10081901. DOI: 10.1155/2023/4988473 . https://www.ncbi.nlm.nih.gov/pubmed/37033470 本文引用 [2]

[6]

Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis[J]. J Clin Endocrinol Metab, 2014, 99(3): 852-860. DOI: 10.1210/jc.2013-3921 . https://www.ncbi.nlm.nih.gov/pubmed/24423364 本文引用 [2]

[7]	Chaplin JE, Kriström B, Jonsson B, et al. Growth hormone treatment improves cognitive function in short children with growth hormone deficiency[J]. Horm Res Paediatr, 2015, 83(6): 390-399. DOI: 10.1159/000375529 . https://www.ncbi.nlm.nih.gov/pubmed/25823753 本文引用 [3]

[8]

Falleti MG, Maruff P, Burman P, et al. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature[J]. Psychoneuroendocrinology, 2006, 31(6): 681-691. DOI: 10.1016/j.psyneuen.2006.01.005 . https://www.ncbi.nlm.nih.gov/pubmed/16621325 本文引用 [2]

[9]	Aghili ZS, Khoshnevisan G, Mostoli R, et al. Growth hormone signaling and clinical implications: from molecular to therapeutic perspectives[J]. Mol Biol Rep, 2025, 52(1): 202. DOI: 10.1007/s11033-025-10304-w . https://www.ncbi.nlm.nih.gov/pubmed/39904816 本文引用 [2]

[10]	Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, et al. Growth hormone and aging: a clinical review[J]. Front Aging, 2025, 6: 1549453. PMCID: PMC12009952. DOI: 10.3389/fragi.2025.1549453 . https://www.ncbi.nlm.nih.gov/pubmed/40260058 本文引用 [1]

[11]	Sharma VM, Vestergaard ET, Jessen N, et al. Growth hormone acts along the PPARγ-FSP27 axis to stimulate lipolysis in human adipocytes[J]. Am J Physiol Endocrinol Metab, 2019, 316(1): E34-E42. PMCID: PMC6417689. DOI: 10.1152/ajpendo.00129.2018 . https://www.ncbi.nlm.nih.gov/pubmed/30325658 本文引用 [1]

[12]	Kopchick JJ, Berryman DE, Puri V, et al. The effects of growth hormone on adipose tissue: old observations, new mechanisms[J]. Nat Rev Endocrinol, 2020, 16(3): 135-146. PMCID: PMC7180987. DOI: 10.1038/s41574-019-0280-9 . https://www.ncbi.nlm.nih.gov/pubmed/31780780 本文引用 [3]

[13]	Li T, Bai H, Fang H, et al. Growth hormone inhibits adipogenic differentiation and induces browning in bovine subcutaneous adipocytes[J]. Growth Horm IGF Res, 2022, 66: 101498. DOI: 10.1016/j.ghir.2022.101498 . https://www.ncbi.nlm.nih.gov/pubmed/36007464 本文引用 [1]

[14]	Wydra A, Czajka-Oraniec I, Wydra J, et al. The influence of growth hormone deficiency on bone health and metabolisms[J]. Reumatologia, 2023, 61(4): 239-247. PMCID: PMC10515129. DOI: 10.5114/reum/170244 . https://www.ncbi.nlm.nih.gov/pubmed/37745147 本文引用 [3]

[15]	Yuen KCJ. Growth hormone and bone: preclinical and clinical perspectives[J]. Endocr Pract, 2025, 31(9): 1197-1206. DOI: 10.1016/j.eprac.2025.07.005 . https://www.ncbi.nlm.nih.gov/pubmed/40669822 本文引用 [5]

[16]	Bolamperti S, Villa I, di Filippo L. Growth hormone and bone: a basic perspective[J]. Pituitary, 2024, 27(6): 745-751. DOI: 10.1007/s11102-024-01464-2 . https://www.ncbi.nlm.nih.gov/pubmed/39476263 本文引用 [2]

[17]	Soler Palacios B, Nieto C, Fajardo P, et al. Growth hormone reprograms macrophages toward an anti-inflammatory and reparative profile in an MAFB-dependent manner[J]. J Immunol, 2020, 205(3): 776-788. DOI: 10.4049/jimmunol.1901330 . https://www.ncbi.nlm.nih.gov/pubmed/32591394 本文引用 [3]

[18]	Hattori N. Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system[J]. Growth Horm IGF Res, 2009, 19(3): 187-197. DOI: 10.1016/j.ghir.2008.12.001 . https://www.ncbi.nlm.nih.gov/pubmed/19144554 本文引用 [2]

[19]	Huang Z, Xiao L, Xiao Y, et al. The modulatory role of growth hormone in inflammation and macrophage activation[J]. Endocrinology, 2022, 163(8): bqac088. DOI: 10.1210/endocr/bqac088 . https://www.ncbi.nlm.nih.gov/pubmed/35695371 本文引用 [3]

[20]	Menezes F, Wasinski F, de Souza GO, et al. The pattern of GH action in the mouse brain[J]. Endocrinology, 2024, 165(7): bqae057. PMCID: PMC11137758. DOI: 10.1210/endocr/bqae057 . https://www.ncbi.nlm.nih.gov/pubmed/38728240 本文引用 [1]

[21]	Aguiar-Oliveira MH, Boguszewski MCS, Rovaris DL, et al. Growth hormone and IGF-1 actions in the brain and neuropsychiatric diseases[J]. Physiology (Bethesda), 2026, 41(1): 3-15. PMCID: PMC12290765. DOI: 10.1152/physiol.00009.2025 . https://www.ncbi.nlm.nih.gov/pubmed/40623083 本文引用 [5]

[22]	Donato J, Kopchick JJ. New findings on brain actions of growth hormone and potential clinical implications[J]. Rev Endocr Metab Disord, 2024, 25(3): 541-553. PMCID: PMC11156798. DOI: 10.1007/s11154-023-09861-x . https://www.ncbi.nlm.nih.gov/pubmed/38060062 本文引用 [3]

[23]

Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association[J]. Circulation, 2016, 134(23): e579-e646. DOI: 10.1161/CIR.0000000000000455 . https://www.ncbi.nlm.nih.gov/pubmed/27832612 本文引用 [1]

[24]

Marra AM, D'Assante R, De Luca M, et al. Growth hormone replacement therapy in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial[J]. JACC Heart Fail, 2025, 13(4): 602-614. DOI: 10.1016/j.jchf.2024.11.017 . https://www.ncbi.nlm.nih.gov/pubmed/40047762 本文引用 [2]

[25]

Ferrigno R, Savanelli MC, Cioffi D, et al. Auxological and metabolic effects of long-term treatment with recombinant growth hormone in children born small for gestational age: a retrospective study[J]. Endocrine, 2024, 84(1): 213-222. DOI: 10.1007/s12020-023-03665-4 . https://www.ncbi.nlm.nih.gov/pubmed/38214878 本文引用 [1]

[26]

Kim S, Kim SJ, Cho KW, et al. Metabolic changes after growth hormone treatment in children with growth hormone deficiency and small for gestational age: LG observational study[J]. Front Endocrinol (Lausanne), 2025, 16: 1661018. PMCID: PMC12672343. DOI: 10.3389/fendo.2025.1661018 . https://www.ncbi.nlm.nih.gov/pubmed/41347132 本文引用 [1]

[27]	Zhou Z, Xiao S, Guo X, et al. Metabolic profiles of Turner syndrome: a real-world cohort study[J]. Medicina Clínica, 2025, 165(4): 107061. DOI: 10.1016/j.medcli.2025.107061 . https://www.ncbi.nlm.nih.gov/pubmed/40570582 本文引用 [1]

[28]	Rosenberg AGW, Passone CGB, Pellikaan K, et al. Growth hormone treatment for adults with Prader-Willi syndrome: a meta-analysis[J]. J Clin Endocrinol Metab, 2021, 106(10): 3068-3091. PMCID: PMC8475230. DOI: 10.1210/clinem/dgab406 . https://www.ncbi.nlm.nih.gov/pubmed/34105729 本文引用 [1]

[29]

Kawai M, Murakami N, Horikawa R, et al. Improvement in body composition of Japanese participants with Prader-Willi syndrome following somatropin treatment: an open-label, multi cohort phase 3 study[J]. Endocr J, 2025, 72(8): 925-935. PMCID: PMC12340246. DOI: 10.1507/endocrj.EJ24-0659 . https://www.ncbi.nlm.nih.gov/pubmed/40436776 本文引用 [1]

[30]

Kühl AM, Tortorella CCS, Almeida CCB, et al. Growth hormone effect on body composition of children born small for gestational age: a systematic review[J]. J Pediatr (Rio J), 2023, 99(3): 219-227. PMCID: PMC10202731. DOI: 10.1016/j.jped.2022.11.010 . https://www.ncbi.nlm.nih.gov/pubmed/36584978 本文引用 [1]

[31]	Ari M, Bakalov VK, Hill S, et al. The effects of growth hormone treatment on bone mineral density and body composition in girls with Turner syndrome[J]. J Clin Endocrinol Metab, 2006, 91(11): 4302-4305. DOI: 10.1210/jc.2006-1351 . https://www.ncbi.nlm.nih.gov/pubmed/16940444 本文引用 [1]

[32]

Kucharska A, Witkowska-Sędek E, Erazmus M, et al. The effects of growth hormone treatment beyond growth promotion in patients with genetic syndromes: a systematic review of the literature[J]. Int J Mol Sci, 2024, 25(18): 10169. PMCID: PMC11432634. DOI: 10.3390/ijms251810169 . https://www.ncbi.nlm.nih.gov/pubmed/39337654 本文引用 [2]

[33]

Stagi S, Ferrari V, Ferrari M, et al. Inside the Noonan "universe": literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns[J]. Front Endocrinol (Lausanne), 2022, 13: 951331. PMCID: PMC9434367. DOI: 10.3389/fendo.2022.951331 . https://www.ncbi.nlm.nih.gov/pubmed/36060964 本文引用 [2]

[34]	Cho MH, An SJ, Shim YS, et al. Impact of growth hormone therapy on bone and body composition in prepubertal children with idiopathic short stature[J]. J Pediatr Endocrinol Metab, 2025, 38(6): 624-630. DOI: 10.1515/jpem-2025-0085 . https://www.ncbi.nlm.nih.gov/pubmed/40256906 本文引用 [1]

[35]

Madeo SF, Zagaroli L, Vandelli S, et al. Endocrine features of Prader-Willi syndrome: a narrative review focusing on genotype-phenotype correlation[J]. Front Endocrinol (Lausanne), 2024, 15: 1382583. PMCID: PMC11082343. DOI: 10.3389/fendo.2024.1382583 . https://www.ncbi.nlm.nih.gov/pubmed/38737552 本文引用 [1]

[36]

Lem AJ, van der Kaay DC, Hokken-Koelega AC. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment[J]. J Clin Endocrinol Metab, 2013, 98(1): 77-86. DOI: 10.1210/jc.2012-2492 . https://www.ncbi.nlm.nih.gov/pubmed/23125290 本文引用 [1]

[37]

Xu Q, Yang Y, Ke J, et al. Effect of growth hormone on bone density and body composition in Chinese patients with transitional growth hormone deficiency[J]. Medicine (Baltimore), 2025, 104(35): e44178. PMCID: PMC12401361. DOI: 10.1097/MD.0000000000044178 . https://www.ncbi.nlm.nih.gov/pubmed/40898510 本文引用 [1]

[38]

Szybiak W, Kujawa B, Miedziaszczyk M, et al. Effect of growth hormone and estrogen replacement therapy on bone mineral density in women with Turner syndrome: a meta-analysis and systematic review[J]. Pharmaceuticals (Basel), 2023, 16(9): 1320. PMCID: PMC10536543. DOI: 10.3390/ph16091320 . https://www.ncbi.nlm.nih.gov/pubmed/37765128 本文引用 [1]

[39]	Weinberg A, Dror N, Motin K, et al. The effect of growth hormone treatment on physical performance indices in children with idiopathic short stature[J]. Pediatr Exerc Sci, 2021, 33(2): 70-73. DOI: 10.1123/pes.2020-0061 . https://www.ncbi.nlm.nih.gov/pubmed/33837161 本文引用 [1]

[40]	Donze SH, Damen L, Mahabier EF, et al. Cognitive functioning in children with Prader-Willi syndrome during 8 years of growth hormone treatment[J]. Eur J Endocrinol, 2020, 182(4): 405-411. DOI: 10.1530/EJE-19-0479 . https://www.ncbi.nlm.nih.gov/pubmed/31961800 本文引用 [1]

[41]	Ayet-Roger A, Joga-Elvira L, Caixàs A, et al. Cognitive and adaptive effects of early growth hormone treatment in Prader-Willi syndrome patients: a cohort study[J]. J Clin Med, 2022, 11(6): 1592. PMCID: PMC8955812. DOI: 10.3390/jcm11061592 . https://www.ncbi.nlm.nih.gov/pubmed/35329918 本文引用 [1]

[42]

van Pareren YK, Duivenvoorden HJ, Slijper FS, et al. Intelligence and psychosocial functioning during long-term growth hormone therapy in children born small for gestational age[J]. J Clin Endocrinol Metab, 2004, 89(11): 5295-5302. DOI: 10.1210/jc.2003-031187 . https://www.ncbi.nlm.nih.gov/pubmed/15531473 本文引用 [1]

[43]	Ross JL, Feuillan P, Kushner H, et al. Absence of growth hormone effects on cognitive function in girls with Turner syndrome[J]. J Clin Endocrinol Metab, 1997, 82(6): 1814-1817. DOI: 10.1210/jcem.82.6.4003 . https://www.ncbi.nlm.nih.gov/pubmed/9177388 本文引用 [1]

[44]

Rovet JF, Van Vliet G. Growth hormone supplementation and psychosocial functioning to adult height in Turner syndrome: a questionnaire study of participants in the Canadian randomized trial[J]. Front Endocrinol (Lausanne), 2019, 10: 125. PMCID: PMC6425861. DOI: 10.3389/fendo.2019.00125 . https://www.ncbi.nlm.nih.gov/pubmed/30930850 本文引用 [1]

[45]	Shemesh-Iron M, Lazar L, Lebenthal Y, et al. Growth hormone therapy and short stature-related distress: a randomized placebo-controlled trial[J]. Clin Endocrinol (Oxf), 2019, 90(5): 690-701. DOI: 10.1111/cen.13944 . https://www.ncbi.nlm.nih.gov/pubmed/30721549 本文引用 [1]

[46]	Phillip M, Abuzzahab MJ, Pietropoli A, et al. Comparative outcomes of GH treatment in pediatric idiopathic short stature and GH deficiency[J]. J Endocr Soc, 2025, 9(10): bvaf133. PMCID: PMC12448476. DOI: 10.1210/jendso/bvaf133 . https://www.ncbi.nlm.nih.gov/pubmed/40980545 本文引用 [1]

[47]

Elbornsson M, Horvath A, Götherström G, et al. Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency[J]. Eur J Endocrinol, 2017, 176(2): 99-109. DOI: 10.1530/EJE-16-0875 . https://www.ncbi.nlm.nih.gov/pubmed/27803031 本文引用 [1]

[48]

Rodrígez JMR, Toda LI, López ID, et al. Adult height and health-related quality of life in patients born small for gestational age treated with recombinant growth hormone[J]. Sci Rep, 2023, 13(1): 3135. PMCID: PMC9950462. DOI: 10.1038/s41598-023-30281-z . https://www.ncbi.nlm.nih.gov/pubmed/36823445 本文引用 [1]

[49]

Bakker NE, Siemensma EP, van Rijn M, et al. Beneficial effect of growth hormone treatment on health-related quality of life in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study[J]. Horm Res Paediatr, 2015, 84(4): 231-239. DOI: 10.1159/000437141 . https://www.ncbi.nlm.nih.gov/pubmed/26279206 本文引用 [1]

[50]

Krantz E, Landin-Wilhelmsen K, Trimpou P, et al. Health-related quality of life in Turner syndrome and the influence of growth hormone therapy: a 20-year follow-up[J]. J Clin Endocrinol Metab, 2019, 104(11): 5073-5083. PMCID: PMC6760289. DOI: 10.1210/jc.2019-00340 . https://www.ncbi.nlm.nih.gov/pubmed/31009056 本文引用 [1]

[51]	Alkan F, Ersoy B, Kızılay DO, et al. Cardiac functions in children with growth hormone deficiency: effects of one year of GH replacement therapy[J]. Growth Horm IGF Res, 2021, 60-61: 101432. DOI: 10.1016/j.ghir.2021.101432 . https://www.ncbi.nlm.nih.gov/pubmed/34715474 本文引用 [1]

[52]

Sävendahl L, Polak M, Backeljauw P, et al. Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER[J]. J Clin Endocrinol Metab, 2021, 106(6): 1728-1741. PMCID: PMC8118578. DOI: 10.1210/clinem/dgab080 . https://www.ncbi.nlm.nih.gov/pubmed/33571362 本文引用 [1]